Cargando…

In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae

Treatment of infections caused by multi-drug resistant (MDR) enterobacteria remains challenging due to the limited therapeutic options available. Drug repurposing could accelerate the development of new urgently needed successful interventions. This work aimed to identify and characterise novel drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gómara-Lomero, Marta, López-Calleja, Ana Isabel, Rezusta, Antonio, Aínsa, José Antonio, Ramón-García, Santiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475115/ https://www.ncbi.nlm.nih.gov/pubmed/37660210 http://dx.doi.org/10.1038/s41598-023-39647-9

Ejemplares similares

FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review
por: Sochacka-Ćwikła, Aleksandra, et al.
Publicado: (2021)

FDA-Approved Pharmacotherapy for Weight Loss Over the Last Decade
por: Idrees, Zarwa, et al.
Publicado: (2022)

Trends in FDA drug approvals over last 2 decades: An observational study
por: Batta, Angelika, et al.
Publicado: (2020)

Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi
por: Planer, Joseph D., et al.
Publicado: (2014)

Synergy of Plant Essential Oils in Antibiotic Therapy to Combat Klebsiella pneumoniae Infections
por: Romo-Castillo, Mariana, et al.
Publicado: (2023)

Insight into Antibiotic Synergy Combinations for Eliminating Colistin Heteroresistant Klebsiella pneumoniae
por: Rajakani, Sahaya Glingston, et al.
Publicado: (2023)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Zidovudine.
por: Sperling, R
Publicado: (1998)

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

In vitro evaluation of antibiotic synergy for carbapenem-resistant Klebsiella pneumoniae clinical isolates
por: Goel, Anku, et al.
Publicado: (2021)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

FDA-Approved Fluorinated Heterocyclic Drugs from 2016 to 2022
por: Rizzo, Carla, et al.
Publicado: (2023)

Re-evaluation of FDA-approved antibiotics with increased diagnostic accuracy for assessment of antimicrobial resistance
por: Heithoff, Douglas M., et al.
Publicado: (2023)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

In Vitro Synergism of Azithromycin Combination with Antibiotics against OXA-48-Producing Klebsiella pneumoniae Clinical Isolates
por: Singkham-in, Uthaibhorn, et al.
Publicado: (2021)

Curcumin-meropenem synergy in carbapenem resistant Klebsiella pneumoniae curcumin-meropenem synergy
por: Gülen, Dumrul, et al.
Publicado: (2021)

Zidovudine-induced myopathy
por: Wiwanitkit, Viroj
Publicado: (2011)

Zidovudine Induced Hyperpigmentation
por: Premjith, Raveendran, et al.
Publicado: (2022)

Morphological, genomic and transcriptomic responses of Klebsiella pneumoniae to the last-line antibiotic colistin
por: Cain, Amy K., et al.
Publicado: (2018)

The Capsule Increases Susceptibility to Last-Resort Polymyxins, but Not to Other Antibiotics, in Klebsiella pneumoniae
por: D’Angelo, Francesca, et al.
Publicado: (2023)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7lf2tikem1qtn4pabsvu8dm6s2